These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 31600554)

  • 21. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.
    Roberts JA; Udy AA; Jarrett P; Wallis SC; Hope WW; Sharma R; Kirkpatrick CM; Kruger PS; Roberts MS; Lipman J
    J Antimicrob Chemother; 2015 May; 70(5):1495-502. PubMed ID: 25608584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A higher dose of vancomycin in continuous infusion is needed in critically ill patients.
    Jeurissen A; Sluyts I; Rutsaert R
    Int J Antimicrob Agents; 2011 Jan; 37(1):75-7. PubMed ID: 21074374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of daptomycin in critically ill patients.
    Soraluce A; Asín-Prieto E; Rodríguez-Gascón A; Barrasa H; Maynar J; Carcelero E; Soy D; Isla A
    Int J Antimicrob Agents; 2018 Aug; 52(2):158-165. PubMed ID: 29572042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vancomycin dosing in critically ill trauma patients: The VANCTIC Study.
    Villanueva RD; Talledo O; Neely S; White B; Celii A; Cross A; Kennedy R
    J Trauma Acute Care Surg; 2019 Nov; 87(5):1164-1171. PubMed ID: 31464871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients.
    Pea F; Furlanut M; Negri C; Pavan F; Crapis M; Cristini F; Viale P
    Antimicrob Agents Chemother; 2009 May; 53(5):1863-7. PubMed ID: 19223642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion.
    De Waele JJ; Danneels I; Depuydt P; Decruyenaere J; Bourgeois M; Hoste E
    Int J Antimicrob Agents; 2013 May; 41(5):434-8. PubMed ID: 23410793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus.
    Salvador E; Oualha M; Bille E; Beranger A; Moulin F; Benaboud S; Boujaafar S; Gana I; Urien S; Zheng Y; Toubiana J; Briand C; Bustarret O; Geslain G; Renolleau S; Treluyer JM; Hirt D
    Clin Microbiol Infect; 2021 Mar; 27(3):413-419. PubMed ID: 32360445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.
    Medellín-Garibay SE; Ortiz-Martín B; Rueda-Naharro A; García B; Romano-Moreno S; Barcia E
    J Antimicrob Chemother; 2016 Feb; 71(2):471-9. PubMed ID: 26568565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients.
    Medellín-Garibay SE; Romano-Moreno S; Tejedor-Prado P; Rubio-Álvaro N; Rueda-Naharro A; Blasco-Navalpotro MA; García B; Barcia E
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
    Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Achievement of Therapeutic Vancomycin Exposure With Continuous Infusion in Critically Ill Children.
    Genuini M; Oualha M; Bouazza N; Moulin F; Treluyer JM; Lesage F; Renolleau S; Benaboud S
    Pediatr Crit Care Med; 2018 Jun; 19(6):e263-e269. PubMed ID: 29394210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
    Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
    Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
    Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF).
    Kirwan M; Munshi R; O'Keeffe H; Judge C; Coyle M; Deasy E; Kelly YP; Lavin PJ; Donnelly M; D'Arcy DM
    Crit Care; 2021 Dec; 25(1):443. PubMed ID: 34930430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
    Lewis SJ; Mueller BA
    J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients.
    Chung J; Oh JM; Cho EM; Jang HJ; Hong SB; Lim CM; Koh YS
    Anaesth Intensive Care; 2011 Nov; 39(6):1030-7. PubMed ID: 22165354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.